News | July 05, 2023
Biocon Biologics expands footprint in emerging markets
Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries
Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries
Dr. Vivek joins Healthium after a stint at Ethicon, Johnson & Johnson
Rare childhood cancer subtype, Ph+ ALL, is found in 3-4% of pediatric cases and 25% of adult cases
The launch of HULIO in the United States is an important milestone for Biocon Biologics
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
The €70 million investment will allow the large-scale manufacturing of high-purity reagents for quality control and testing for biopharma customers, increasing annual output by several thousand tons
Rapid card test kits for iScreen malaria card antigen (Pf/Pv) & iScreen dengue NS1
Granules India sponsored an initiative to ignite a drug-free revolution and contribute towards an empowered society
Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite
Subscribe To Our Newsletter & Stay Updated
